The high prevalence of metabolic syndrome in polymyositis

Clinical and Experimental Rheumatology

Volumn 32, Issue 1, 2014, Pages 82-87

  de Souza, Fernando H C ^a   Shinjo, Samuel K ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiovascular diseases; Inflammatory myopathies; Metabolic syndrome; Polymyositis

Indexed keywords

ADULT; AGED; BRAZIL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; POLYMYOSITIS; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; PREVALENCE; RISK FACTORS; TIME FACTORS;

EID: 84894045043     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. DIMACHKIE MM, BAROHN RJ: Idiopathic inflammatory myopathies. Front Neurol Neurosci 2009; 26: 126-46.
2. PRIETO S, GRAU JM: The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010; 9: A330-4.
3. GAUBITZ M: Epidemiology of connective tissue disorders. Rheumatology (Oxford) 2006; 45 (Suppl. 3): iii3-4.
4. REAVEN GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
5. GRUNDY SM: Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-36.
6. CAMERON AJ, SHAW JE, ZIMMET PZ: The metabolic syndrome: Prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004; 33: 351-75.
7. ISOMAA B, ALMGREN P, TUOMI T et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
8. FORD ES, GILES WH, MOKDAD AH: Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-9.
9. CHUNG CP, OESER A, SOLUS JF et al.: Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196: 756-63.
10. GRUNDY SM, CLEEMAN JI, DANIELS SR et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
11. TOMS TE, PANOULAS VF, JOHN H, DOUGLAS KM, KITAS GD: Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60-more than just an antiinflammatory effect? A cross sectional study. Arthritis Res Ther 2009; 11: R110.
12. DESSEIN PH, STANWIX AE, JOFFE BI: Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2765-75.
13. de MORAES MT, de SOUZA FHC, de BARROS TBM, SHINJO SK: An analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res 2013; 65: 793-9.
14. CHEN YJ, WU CY, SHEN JL, CHU SY, CHEN CK, CHANG YT et al.: Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144: 1571-5.
15. MANZI S, SELZER F, SUTTON-TYRRELL K et al.: Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.
16. SABIO J, ZAMORA-PASADAS M, JIMéNEZJáIMEZ J et al.: Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008; 17: 849-959.
17. ESDAILE JM, ABRAHAMOWICZ M, GRODZICKY T et al.: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44: 2331-7.
18. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
19. LEGG AT, MERRIL JB: Physical therapy in infantile paralysis. In: Principles and Practice of Physical Therapy. Hagerstown: Mock Pemberton and Coulter; 1932.
20. BRUCE B, FRIES JF: The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003; 1: 20.
21. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection and treatment of high blood cholesterol in adults (adult treatment Panel III). JAMA 2001; 285: 2486-97.
22. CRAIG CL, MARSHALL AL, SJOSTROM M et al.: International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381-95.
23. MATSUDO SM, ARAúJO T, MATSUDO VR et al.: Questionário internacional de atividade física (IPAC): estudo de validade e reprodutibilidade no Brasil. Rev Bras At Física & Saúde 2001; 6: 5-18.
24. PETERS MJ, SYMMONS DP, McCAREY D et al.: EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
25. WANG H, TANG J, CHEN X, LI F, LUO J: Lipid profiles in untreated patients with dermatomyositis. J Eur Acad Dermatol Venereol 2013; 27: 175-9.
26. DESSEIN PH, NORTON GR, JOFFE BI, ABDOOL-CARRIM AT, WOODWISS AJ, SOLOMON A: Metabolic cardiovascular risk burden and atherosclerosis in African black and Caucasian women with rheumatoid artrhtiis: a cross-sectional study. Clin Exp Rheumatol 2013; 31: 53-61.
27. WESTHOVENS R, NIJS J, TAELMAN V, DEQUEKER J: Body composition in rheumatoid arthritis. Br J Rheumatol 1997; 36: 444-8.
28. KONTUNEN P, VUOLTEENAHO K, NIEMINEN R et al.: Resistin is linked to inflammation, and leptin to metabolic syndrome, in women with inflammatory arthritis. Scand J Rheumatol 2011; 40: 256-62.
29. LINKLATER H, PIPITONE N, ROSE MR et al.: Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 2013; 31:767-9.